AAV Therapy Development: Speed vs Discipline

Momentum can accelerate innovation. Discipline helps sustain it. As AAV-based therapies continue to advance, organizations face important decisions around development strategy, manufacturing readiness, and long-term scalability. Our latest blog post examines the balance between speed and discipline required to keep programs moving forward. Read the blog post: https://ald.bio/4wGwlia #AAV #GeneTherapy #CGT #Bioprocessing #Biomanufacturing #Biotech

BioLife Solutions Reports Second Quarter 2026 Financial Results Total revenue of $28.5 million, up 21% over Q2 2025 Repligen to acquire BioLife and the proposed transaction is expected to close in the fourth quarter of 2026 *Due to the pending acquisition of BioLife by Repligen, BioLife will not be hosting a conference call. Read the press release: https://lnkd.in/dA8Pukfe

#PollAnswer: The correct answer is 𝗖) $𝟮.𝟮 𝗺𝗶𝗹𝗹𝗶𝗼𝗻. 𝗖𝗮𝘀𝗴𝗲𝘃𝘆, the world's first approved #CRISPR-based therapy, is priced at approximately $2.2 million per patient. Developed to treat sickle cell disease and transfusion-dependent beta thalassemia, it represents a landmark achievement in #gene editing—and a glimpse into the future of precision #medicine. But it also highlights a critical challenge: scientific breakthroughs alone are not enough. Affordability, manufacturing capacity, #regulatory pathways, and equitable access all determine whether revolutionary #therapies can truly reach the patients who need them. At @Mumbai Biocluster, we're working toward that future by creating an ecosystem that accelerates research, enables translational science, and supports the development and delivery of next-generation therapeutics—from the laboratory to the patient. Partner with us to create lasting impact: https://lnkd.in/dUbKrNUa Ratnesh Jain | Prajakta Dandekar Jain | Institute Of Chemical Technology | Ashwini Patil #TriviaTuesday #MumbaiBiocluster #CRISPR #GeneEditing #CellAndGeneTherapy #AdvancedTherapies #PrecisionMedicine #Biotechnology #Biologics2026

Meet iLite® technology by Svar Life Science—a cell-based reporter gene system to streamline biopharmaceutical development. Here's what makes iLite a game-changer for drug discovery and safety testing: Dual-Reporter Normalization: Internal controls compensate for cell count variations and serum matrix effects, delivering precise, reproducible results. Assay-Ready Convenience: Frozen, ready-to-use cells eliminate time-consuming cell culture and maintenance. Versatile Applications: Perfect for assessing biotherapeutics, neutralising antibodies (NAb), complement activation, and functional assays (like ADCC). By removing the friction of cell culturing, teams can focus entirely on data, accelerating the pipeline from lab to clinic. 👉 Explore the full range of bioassays here: svarlifescience.com #Biotech #DrugDiscovery #Bioassays #PharmaInnovation #Immunogenicity #SvarLifeScience

Can AI transform the way antibodies are discovered? Hear Shantanu Kumar explain how CelAbGen is leading the change. Gaurav Kharya Tanveer Ahmad Nisha Chaudhary Juli Gupta Akshita Sinha Cellogen Therapeutics #CelAbGen #CellogenTherapeutics #AI #Biotech #AntibodyDiscovery #DrugDiscovery #LifeSciences #HealthcareInnovation #PrecisionMedicine #Innovation

The life sciences and healthcare sector is going through a period of rapid advance and innovation, and healthcare logistics are central to every new clinical trial, innovative biopharma solution and revolutionary gene therapy. Success requires more than just transport.   Logistics for life sciences demand unparalleled levels of excellence, stringent regulations, and risk management. Product integrity is paramount. Whether it's small-scale lab samples or large-volume pharma distribution, the end-to-end supply chain must deliver continuity, visibility and 100% control. ©️: DHL 🔗

4D Molecular Therapeutics reports positive two-year P-IIb (PRISM) Data for 4D-150 gene therapy, demonstrating sustained vision and anatomical control with up to 87% reduction in anti-VEGF treatment burden in wet age-related macular degeneration Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #4dmoleculartherapeutics #phase2b #prism #4d150 #genetherapy #wetamd #4front #phase3 #clinicaltrial #ophthalmology #retinaldisease #biotech https://lnkd.in/gz-3CCs3

8/4/26: DNA Script And Leading Healthcare Solutions Provider Awarded Up To $26M By ARPA-H To Advance Cell-Free DNA Bioproduction. FLASH Program, In Collaboration With GE HealthCare, To Support Development Of Faster, Distributed DNA Manufacturing For Next-Generation Therapies. More at https://lnkd.in/gzrARi2s

The next CAR-T factory may be the patient. That is the promise of in vivo CAR-T: instead of collecting a patient’s T cells, genetically engineering, expanding them outside the body and then re-infusing them, a targeted vector delivers the CAR instructions directly to T cells inside the patient. FDA clearance of Umoja Biopharma’s IND for UB-VV400, a CD22-directed in vivo CAR-T candidate for adults with r/r B-cell malignancies, is an important step toward testing this concept in a Phase 1/2 trial. If successful, this model could shorten time to treatment and improve scalability. It does not eliminate manufacturing ... It changes what is manufactured, where cell engineering happens, and how the therapy must be controlled. And this shift raises a new set of critical questions: Can gene delivery be restricted to the intended cells? Can CAR-T expansion and persistence be controlled? How should dose, bio-distribution, off-target transduction, immunogenicity, and long-term safety be evaluated? At BCT, we see this development not as the replacement of conventional CAR-T, but as the emergence of a more programmable therapeutic model- one in which cell engineering and targeted gene delivery increasingly converge. The factory may move. But the need for control only grows. #CGT #CART #CD22 #GMP #BiruniCell

The future of AI-driven drug discovery is accelerating faster than ever. 🚀 I am thrilled to share a major milestone for our One Billion Cell Atlas (1BCA) program at Illumina. As of the end of Q2 2026, our 1BCA dataset has officially surpassed 350 million cells—a significant jump from our previous 200 million milestone. https://lnkd.in/ghbEexBv This growth is made even more exciting by the expansion of our collaborative ecosystem. I would like to extend a warm welcome to our new partners who have joined the 1BCA consortium, including Formation Bio and two other industry-leading companies. Their expertise will be invaluable as we continue to redefine what’s possible in AI-driven drug development. By scaling our causal perturbation data to this level alongside such visionary partners, we are effectively addressing critical bottlenecks in drug discovery—enabling us to better understand what works, why it works, and which patient populations are most likely to benefit. I’m incredibly grateful to my brilliant colleagues at the Illumina AI Lab for their dedication to pushing the boundaries of what’s possible in biology. Together, we are building the foundational engine for the next generation of precision medicines. #Illumina #1BCA #BioInsight #DrugDiscovery #Genomics #AI #SingleCell #PrecisionMedicine